Biofrontera Inc (BFRI)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Biofrontera Inc Stock (BFRI) Company Profile

Biofrontera Inc

Healthcare (1200)

781-245-1325

120 PRESIDENTIAL WAY,, WOBURN

Prossima data di guadagno

Ultimi documenti SEC

BFRI's Discussions on Twitter

Confronta BFRI con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BFRI Biofrontera Inc	0.99	7.67M	34.07M	-20.13M	-24.90M	-17.12
ZTS Zoetis Inc	176.74	80.59B	9.15B	2.43B	2.31B	4.92
HLN Haleon Plc Adr	9.72	44.17B	14.26B	1.55B	0	0.3327
TAK Takeda Pharmaceutical Co Adr	13.57	42.61B	30.27B	1.93B	3.45B	0.444
TEVA Teva Pharmaceutical Industries Ltd Adr	16.57	18.77B	16.77B	-959.00M	1.37B	-2.00
VTRS Viatris Inc	13.22	15.73B	15.05B	-883.30M	1.89B	1.53

Biofrontera Inc Borsa (BFRI) Ultime notizie

Biofrontera Inc Azioni (BFRI) Dati Finanziari

Biofrontera Inc (BFRI)

Biofrontera Inc Stock (BFRI) Company Profile

Confronta BFRI con altri titoli

Biofrontera Inc Borsa (BFRI) Ultime notizie

Biofrontera Closes a $4.2 Million Senior Secured Convertible Note - citybiz

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note - GlobeNewswire

Biofrontera Secures $4.2M for Strategic Growth Initiatives - TipRanks

Biofrontera Secures $4.2M Financing Through Convertible Note Deal with Key Shareholders | BFRI Stock News - StockTitan

Biofrontera AG announced that it has received $4.2 million in funding - Marketscreener.com

Biofrontera Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St

Earnings call: Biofrontera reports modest revenue growth in Q3 2024 - Investing.com

Biofrontera Inc. (NASDAQ:BFRI) Q3 2024 Earnings Call Transcript - Insider Monkey

Biofrontera Inc. (BFRI) Quarterly 10-Q Report - Quartzy

ARMISTICE CAPITAL, LLC Acquires New Stake in Biofrontera Inc - GuruFocus.com

Biofrontera Inc. Reports Q3 2024 Earnings Growth - TipRanks

Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates - MSN

Biofrontera Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update - GlobeNewswire

Biofrontera Reports Record Ameluz Volume, Phase 3 Study Shows 76% Clearance Rate | BFRI Stock News - StockTitan

Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc. - GuruFocus.com

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 - Yahoo Finance

Biofrontera reports breakthrough in skin cancer treatment By Investing.com - Investing.com Australia

Biofrontera stock climbs as drug-device succeeds in Phase III skin cancer trial - Yahoo Finance

Biofrontera Announces Promising Phase 3 Study Results - TipRanks

Biofrontera reports breakthrough in skin cancer treatment - Investing.com

Biofrontera announces results in Phase 3 study of Ameluz-PDT for sBCC - TipRanks

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - GlobeNewswire

Actinic Keratosis Treatment Market Expected to Reach Huge - openPR

Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc - Yahoo Finance

Biofrontera locks phase 3 sBCC study database for analysis By Investing.com - Investing.com Australia

Biofrontera locks phase 3 sBCC study database for analysis - Investing.com India

Biofrontera Inc. Announces Database Lock Of Phase 3 Study - GlobeNewswire

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - StockTitan

BFRI’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle

Mass. Biotech Receives FDA Approval - Streetwise Reports

Roth/MKM sets Biofrontera target at $16, reiterates buy rating By Investing.com - Investing.com South Africa

Roth/MKM sets Biofrontera target at $16, reiterates buy rating - Investing.com India

What was Biofrontera Inc (BFRI)’s performance in the last session? - US Post News

Biofrontera says FDA approves use of up to 3 tubes of Ameluz topical gel 10% - TipRanks

Biofrontera’s Ameluz Gel FDA Approval for Higher Dosage - TipRanks

FDA approves expanded use of Biofrontera's Ameluz for AK - Investing.com

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - The Manila Times

FDA approves expanded use of Biofrontera's Ameluz for AK By Investing.com - Investing.com UK

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s - GlobeNewswire

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - StockTitan

BFRI’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle

Ratio Examination: Biofrontera Inc (BFRI)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Biotech Stocks Facing FDA Decision In October 2024 - RTTNews

Tilray Brands (TLRY) Stock Surges Amidst Market Volatility - GuruFocus.com

ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times

Biofrontera Second Quarter 2024 Earnings: €0.023 loss per share (vs €0.12 profit in 2Q 2023) - Yahoo Finance

Five PDUFA dates on FDA’s October agenda - BioCentury

Photodynamic Therapy Market Share, Trends, Size, Major Players And Forecast To 2033 - WhaTech

Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story - Simply Wall St

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference - StockTitan

Biofrontera Inc Azioni (BFRI) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a BFRI